Ahmed Hamdy Biography and Net Worth

Ahmed Hamdy, MD is the Chief Executive Officer and Chairman of the board of directors of Vincerx. Dr Hamdy has served as Vincerx’s Chief Executive Officer and as a member Vincerx’s board of directors since March 2019. Before that, Dr Hamdy co-founded Acerta Pharma, a pharmaceutical development company and member of the AstraZeneca plc, and served as its head of early clinical development from January 2015 to June 2019, as chief executive officer from February 2013 to January 2015, as chief medical officer from February 2013 to January 2015 and as a member of the board from February 2013 to February 2016. Before that, Dr Hamdy served as chief medical officer of Pharmacyclics LLC, a biopharmaceutical company, from March 2008 to June 2011. Dr Hamdy has served as a clinical advisor and member of the board of directors of Andes Biotechnologies, a nucleic acid-based drug discovery and development company, since September 2016, as a member of the Dean’s Council of the Jack Baskin School of Engineering at the University of California, Santa Cruz, since April 2019, and as a member of the Palo Alto Medical Foundation President’s Council since March 2016.

Dr. Hamdy received a MBBCH from the KasrAlainy School of Medicine at the University of Cairo, Egypt.

What is Ahmed Hamdy's net worth?: The estimated net worth of Ahmed Hamdy is at least $86,145.13 as of August 9th, 2023. Dr. Hamdy owns 90,660 shares of Vincerx Pharma stock worth more than $86,145 as of April 17th. This net worth estimate does not reflect any other assets that Dr. Hamdy may own. Additionally, Dr. Hamdy receives an annual salary of $609,840.00 as CEO at Vincerx Pharma. Learn More about Ahmed Hamdy's net worth.
How old is Ahmed Hamdy?: Dr. Hamdy is currently 59 years old. There are 3 older executives and no younger executives at Vincerx Pharma. Learn More on Ahmed Hamdy's age.
What is Ahmed Hamdy's salary?: As the CEO of Vincerx Pharma, Inc., Dr. Hamdy earns $609,840.00 per year. Learn More on Ahmed Hamdy's salary.
How do I contact Ahmed Hamdy?: The corporate mailing address for Dr. Hamdy and other Vincerx Pharma executives is 260 SHERIDAN AVENUE SUITE 400, PALO ALTO CA, 94306. Vincerx Pharma can also be reached via phone at 650-800-6676. Learn More on Ahmed Hamdy's contact information.
Has Ahmed Hamdy been buying or selling shares of Vincerx Pharma?: Ahmed Hamdy has not been actively trading shares of Vincerx Pharma over the course of the past ninety days. Most recently, on Wednesday, August 9th, Ahmed Md Hamdy bought 16,900 shares of Vincerx Pharma stock. The stock was acquired at an average cost of $0.95 per share, with a total value of $16,055.00. Following the completion of the transaction, the insider now directly owns 90,660 shares of the company's stock, valued at $86,127. Learn More on Ahmed Hamdy's trading history.
Who are Vincerx Pharma's active insiders?: Vincerx Pharma's insider roster includes Laura Bushnell (Director), Ahmed Hamdy (CEO), Raquel Izumi (Insider), Andrew McDonald (Director), Alexander Seelenberger (CFO), and Tom Thomas (Insider). Learn More on Vincerx Pharma's active insiders.
Are insiders buying or selling shares of Vincerx Pharma?: During the last year, Vincerx Pharma insiders bought shares 2 times. They purchased a total of 27,400 shares worth more than $26,030.00. The most recent insider tranaction occured on August, 11th when insider Alexander A Seelenberger bought 10,500 shares worth more than $9,975.00. Insiders at Vincerx Pharma own 20.6% of the company. Learn More about insider trades at Vincerx Pharma.
Information on this page was last updated on 8/11/2023.

Ahmed Hamdy Insider Trading History at Vincerx Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/9/2023	Buy	16,900	$0.95	$16,055.00	90,660
12/14/2022	Buy	35,280	$0.87	$30,693.60	73,760
6/23/2022	Buy	24,200	$1.41	$34,122.00	38,480
12/22/2021	Buy	6,450	$10.02	$64,629.00

Ahmed Hamdy Buying and Selling Activity at Vincerx Pharma

Vincerx Pharma Company Overview

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Today's Range

Now: $0.95

$0.91

$0.98

50 Day Range

MA: $4.19

$0.87

$8.06

2 Week Range

Now: $0.95

$0.61

$9.37

Volume

354,094 shs

Average Volume

1,316,408 shs

Market Capitalization

$20.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

AI “wealth window” is closing soon!

From Paradigm Press | Ad

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

Ahmed Hamdy Biography and Net Worth

What is Ahmed Hamdy's net worth?

How old is Ahmed Hamdy?

What is Ahmed Hamdy's salary?

How do I contact Ahmed Hamdy?

Has Ahmed Hamdy been buying or selling shares of Vincerx Pharma?

Who are Vincerx Pharma's active insiders?

Are insiders buying or selling shares of Vincerx Pharma?